Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Hier

Showing results (81-90 of 84) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 84 results.
Ebiomedicine|November 28, 2022
Immune-based classification of HPV-associated oropharyngeal cancer with implications for biomarker-driven treatment de-intensificationPeter Y F Zeng, Matthew J Cecchini, John W Barrett, et al.
JAMA Oncology|April 28, 2022
Assessment of Toxic Effects and Survival in Treatment Deescalation With Radiotherapy vs Transoral Surgery for HPV-Associated Oropharyngeal Squamous Cell Carcinoma: The ORATOR2 Phase 2 Randomized Clinical TrialDavid A Palma, Eitan Prisman, Eric Berthelet, et al.
BMC Cancer|February 16, 2020
Treatment de-escalation for HPV-associated oropharyngeal squamous cell carcinoma with radiotherapy vs. trans-oral surgery (ORATOR2): study protocol for a randomized phase II trialAnthony C Nichols, Pencilla Lang, Eitan Prisman, et al.
Frontiers in Public Health|October 13, 2017
The Consensus from the <i>Mycobacterium avium ssp. paratuberculosis</i> (MAP) Conference 2017J Todd Kuenstner, Saleh Naser, William Chamberlin, et al.
Pageof 9

Showing results (81-90 of 84) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 84 results.
Ebiomedicine|November 28, 2022
Immune-based classification of HPV-associated oropharyngeal cancer with implications for biomarker-driven treatment de-intensificationPeter Y F Zeng, Matthew J Cecchini, John W Barrett, et al.
JAMA Oncology|April 28, 2022
Assessment of Toxic Effects and Survival in Treatment Deescalation With Radiotherapy vs Transoral Surgery for HPV-Associated Oropharyngeal Squamous Cell Carcinoma: The ORATOR2 Phase 2 Randomized Clinical TrialDavid A Palma, Eitan Prisman, Eric Berthelet, et al.
BMC Cancer|February 16, 2020
Treatment de-escalation for HPV-associated oropharyngeal squamous cell carcinoma with radiotherapy vs. trans-oral surgery (ORATOR2): study protocol for a randomized phase II trialAnthony C Nichols, Pencilla Lang, Eitan Prisman, et al.
Frontiers in Public Health|October 13, 2017
The Consensus from the <i>Mycobacterium avium ssp. paratuberculosis</i> (MAP) Conference 2017J Todd Kuenstner, Saleh Naser, William Chamberlin, et al.
Pageof 9